Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07739121
Recruiting Observational

Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations

NCT07739121 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-05-01
Last updated
2026-07-31

Condition(s) studied

Breast NeoplasmsLung NeoplasmsUrologic NeoplasmsProstatic NeoplasmsUrinary Bladder NeoplasmsKidney NeoplasmsDigestive System NeoplasmsGenital NeoplasmsArtifical IntelligenceLarge Language ModelsDecision MakingDecision Support Systems, Clinical

Investigational drug(s) / intervention(s)

Multidisciplinary tumour boardsFrontier large language models

Multidisciplinary tumour boards: Two independent tumour boards per localisation (10 boards in total) issue a categorical recommendation for every synthetic case. Where both boards agree, their consensus defines the reference standard; where they differ, the case-domain is classified as EQUIPOISE and analysed separately.

Frontier large language models: Five frontier LLMs (GPT-5.6, Claude Fable 5, Gemini 3.1 Pro, DeepSeek V4 Pro, Llama 4 Maverick) each receive the identical structured input for every case, three times in independent sessions, under locked prompts, versions and settings.

Study summary

BEACON (Benchmarking AI for Clinical Oncology decisioNmaking) is a prospective, multicentre, comparative, blinded, non-interventional benchmark evaluating the treatment recommendations of five frontier large language models (LLMs) against the recommendations of multidisciplinary tumour boards (RCP) in oncology treatment planning. One hundred standardised synthetic cases (20 per localisation, across breast, lung, urological, digestive and gynaecological cancers) are submitted as identical structured input to two independent tumour boards per localisation and to five frontier LLMs. Each recommendation - human or model - is decomposed into five predefined decision domains (intent, surgery, radiotherapy, systemic therapy, work-up and biomarkers) and scored 0/1/2 for concordance against a two-tier reference: the consensus of the two tumour boards, complemented by an a priori locked guideline matrix (ESMO, NCCN). The primary endpoint is domain-level concordance between LLM and RCP consensus, expressed as a linearly weighted Cohen's kappa. A co-primary safety endpoint captures the proportion of recommendations carrying serious harm potential, because concordance alone can conceal dangerous errors. Because expert boards may disagree with one another on identical cases, model performance is always interpreted against the human consensus. BEACON is designed as reusable, openly licensed, pre-registered infrastructure: all synthetic cases, evaluation rubrics, the locked guideline matrix, scoring algorithms and verbatim prompts are released for full reproducibility.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Synthetic oncology case within one of the five predefined localisations (breast, lung, urological, digestive, gynaecological). * Complete structured schema: UICC 8th-edition stage, biomarkers, ECOG performance status, comorbidities and a standardised clinical question. * A clinically answerable treatment-planning question that is mappable to the locked guideline matrix. Exclusion Criteria: * Case outside the five predefined localisations. * Incomplete, internally inconsistent or ambiguous schema. * Duplicate or near-duplicate of an existing case in the set. * Question not resolvable by current guidelines.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hopital Européen Georges Pompidou Paris France Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07739121 on ClinicalTrials.gov ↗ ← All trials in France